Anaconda Biomed announced today that it received CE mark approval to commercialize its ANA5 funnel catheter in Europe.
The company designed ANA5, a next-generation funnel catheter, to optimize mechanical thrombectomy. It maximizes clot capture with its vessel-matching diameter funnel. Simultaneously, it enables antegrade flow arrest and offers the potential for flow reversal to enhance aspiration-assisted clot retrieval. ANA5 promotes improved clot capture and removal through its unique proprietary geometry.
Barcelona, Spain–based Anaconda says it engineered the expandable and collapsible funnel catheter for interventional neurovascular procedures. ANA5 Advanced Neurovascular Access (ANA) features a radiopaque nitinol braid funnel. Covered with a polymeric coating, it enables local flow arrest.
The device remains investigational and not for sale in the U.S. However, Anaconda earlier this year enrolled the first patient in a U.S. clinical trial for the catheter.
“Receiving CE Mark approval is a pivotal achievement for Anaconda Biomed that advances our mission to innovate in the interventional management of acute ischemic stroke,” said Trent Reutiman, Anaconda Biomed CEO. “This milestone reflects the strength of our science and the dedication of our team. We now have the capability of making ANA5 available to clinicians across Europe, bringing this innovative technology to broader stroke application.”
